Terms: = Sarcomas AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src
518 results:
1. Phase separation of SHP2E76K promotes malignant transformation of mesenchymal stem cells by activating mitochondrial complexes.
Kan C; Tan Z; Liu L; Liu B; Zhan L; Zhu J; Li X; Lin K; Liu J; Liu Y; Yang F; Wong M; Wang S; Zheng H
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38451719
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract] [Full Text] [Related]
3. Re-expression of epigenetically silenced PTPRR by histone acetylation sensitizes RAS-mutant lung adenocarcinoma to SHP2 inhibition.
Du T; Hu X; Hou Z; Wang W; You S; Wang M; Ji M; Xue N; Chen X
Cell Mol Life Sci; 2024 Jan; 81(1):64. PubMed ID: 38280930
[TBL] [Abstract] [Full Text] [Related]
4. CSK may be a potential prognostic biomarker reflecting the immune status of gastric cancer.
Yan X; Huan J
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):221-230. PubMed ID: 38235873
[TBL] [Abstract] [Full Text] [Related]
5. Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and
Pang H; Wu H; Zhan Z; Wu T; Xiang M; Wang Z; Song L; Wei B
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186298
[TBL] [Abstract] [Full Text] [Related]
6. [Bioinformatics analysis and identification to immune-related markers of osteoporosis].
Sun J; Cong S; Luo L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Dec; 39(12):1108-1113. PubMed ID: 38140871
[TBL] [Abstract] [Full Text] [Related]
7. Compartment-specific multiomic profiling identifies src and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract] [Full Text] [Related]
8. Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
[TBL] [Abstract] [Full Text] [Related]
9. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y; Liu QP; Xie H; Ding J
Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
[TBL] [Abstract] [Full Text] [Related]
10. A multiomic investigation of lung adenocarcinoma molecular subtypes.
Liang KH; Luo YH; Wang ML; Chiou SH; Chen YM; Hsu HS
J Chin Med Assoc; 2024 Jan; 87(1):33-39. PubMed ID: 37991388
[TBL] [Abstract] [Full Text] [Related]
11. Identification of hub genes and pathways associated with cellular senescence in diabetic foot ulcers via comprehensive transcriptome analysis.
Huang Y; Wang D; Zhang W; Yuan X; Li K; Zhang Y; Zeng M
J Cell Mol Med; 2024 Jan; 28(1):e18043. PubMed ID: 37985432
[TBL] [Abstract] [Full Text] [Related]
12. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
13. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
14. Network pharmacology and molecular docking to explore the mechanism of Sheng Xue Bao mixture against iron deficiency anemia.
Wang Y; Qinqin H; Wang H; Zhang H; Zhang X; Liu W; Xiang Z; Gu Y
Medicine (Baltimore); 2023 Sep; 102(37):e35012. PubMed ID: 37713882
[TBL] [Abstract] [Full Text] [Related]
15. Intensified Adjuvant Treatment for High-Risk Resected Cutaneous Angiosarcoma of the Head and Neck.
El Shatanofy M; Thakkar P; Patel V; Joshi A; Goodman J; Siegel R; Haroun F; Ojong-Ntui M; Goyal S; Bauman J; Rao YJ
Otolaryngol Head Neck Surg; 2023 Nov; 169(5):1225-1233. PubMed ID: 37464928
[TBL] [Abstract] [Full Text] [Related]
16. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and src Family Kinase YES in Rhabdomyosarcoma.
Akshintala S; Sundby RT; Bernstein D; Glod JW; Kaplan RN; Yohe ME; Gross AM; Derdak J; Lei H; Pan A; Dombi E; Palacio-Yance I; Herrera KR; Miettinen MM; Chen HX; Steinberg SM; Helman LJ; Mascarenhas L; Widemann BC; Navid F; Shern JF; Heske CM
Clin Cancer Res; 2023 Sep; 29(17):3329-3339. PubMed ID: 37398992
[TBL] [Abstract] [Full Text] [Related]
17. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.
Black LE; Longo JF; Anderson JC; Carroll SL
Am J Pathol; 2023 Sep; 193(9):1298-1318. PubMed ID: 37328102
[TBL] [Abstract] [Full Text] [Related]
18. v-src delocalizes Aurora B by suppressing Aurora B kinase activity during monopolar cytokinesis.
Ota R; Watanabe T; Wazawa Y; Kuwajima H; Honda T; Soeda S; Saito Y; Yuki R; Fukumoto Y; Yamaguchi N; Yamaguchi N; Nakayama Y
Cell Signal; 2023 Sep; 109():110764. PubMed ID: 37315749
[TBL] [Abstract] [Full Text] [Related]
19. E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways.
Huang TT; Chen CM; Lin SS; Lan YW; Cheng HC; Choo KB; Wang CC; Huang TH; Chong KY
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298555
[TBL] [Abstract] [Full Text] [Related]
20. Traditional Chinese Medicine Targeting Sarcoma Virus Oncogene-related Diseases.
Wang Y; Wang X; Su K; Yang Y
Curr Cancer Drug Targets; 2023; 23(10):751-763. PubMed ID: 37170983
[TBL] [Abstract] [Full Text] [Related]
[Next]
